Literature DB >> 597963

Changes of activity of daunorubicin, adriamycin and stereoisomers following the introduction or removal of hydroxyl groups in the amino sugar moiety.

A Di Marco, A M Casazza, T Dasdia, A Necco, G Pratesi, P Rivolta, A Velcich, A Zaccara, F Zunino.   

Abstract

The results of a study of the effects of hydroxyl groups at positions, 2, 4 and 6 of the amino sugar on the activity of daunorubicin, adriamycin, and stereoisomers are presented. While the 4'-deoxy derivatives showed a slightly increased biological activity as compared with the parent compounds, the derivatives containing an additional hydroxyl group were less active. It is suggested that the changes in the polarity and in the DNA binding ability of these derivatives are the main factors accounting for the difference in the in vivo activity. The possible relations among the pKa values, the DNA binding properties, and the cellular uptake of the compounds are discussed with particular reference to their therapeutic effectiveness.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 597963     DOI: 10.1016/0009-2797(77)90052-7

Source DB:  PubMed          Journal:  Chem Biol Interact        ISSN: 0009-2797            Impact factor:   5.192


  19 in total

1.  Intracellular pH and the control of multidrug resistance.

Authors:  S Simon; D Roy; M Schindler
Journal:  Proc Natl Acad Sci U S A       Date:  1994-02-01       Impact factor: 11.205

2.  Phase I trial with 4'-deoxydoxorubicin (esorubicin).

Authors:  M Rozencweig; N Crespeigne; Y Kenis
Journal:  Invest New Drugs       Date:  1983       Impact factor: 3.850

3.  Pathway Engineering of Anthracyclines: Blazing Trails in Natural Product Glycodiversification.

Authors:  Katelyn V Brown; Benjamin Nji Wandi; Mikko Metsä-Ketelä; S Eric Nybo
Journal:  J Org Chem       Date:  2020-09-22       Impact factor: 4.354

Review 4.  Anthracycline antitumour agents. A review of physicochemical, analytical and stability properties.

Authors:  J Bouma; J H Beijnen; A Bult; W J Underberg
Journal:  Pharm Weekbl Sci       Date:  1986-04-25

5.  Pharmacokinetics of idarubicin (4-demethoxydaunorubicin; IMI-30; NSC 256439) following intravenous and oral administration in patients with advanced cancer.

Authors:  H C Gillies; D Herriott; R Liang; K Ohashi; H J Rogers; P G Harper
Journal:  Br J Clin Pharmacol       Date:  1987-03       Impact factor: 4.335

6.  Comparative metabolism and elimination of adriamycin and 4'-epiadriamycin in the rat.

Authors:  T W Sweatman; M Israel
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

7.  Phase II trial of esorubicin (4'deoxydoxorubicin, DxDx) in patients with small cell lung cancer.

Authors:  J R Rigas; M G Kris; R J Gralla; R T Heelan; L D Marks
Journal:  Invest New Drugs       Date:  1991-05       Impact factor: 3.850

8.  Fluorescence assays and pharmacokinetic studies of 4'-deoxydoxorubicin and doxorubicin in organs of mice bearing solid tumors.

Authors:  F Formelli; C Pollini; A M Casazza; A di Marco; A Mariani
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

9.  Comparison of the intracellular pharmacokinetics of doxorubicin and 4'-epi-doxorubicin in patients with acute leukemia.

Authors:  U Tidefelt; B Sundman-Engberg; C Paul
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

10.  Effect of pH and moderate hyperthermia on doxorubicin, epirubicin and aclacinomycin A cytotoxicity for Chinese hamster ovary cells.

Authors:  L Kleeberger; E M Röttinger
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.